gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 20 May 2015.

Apolipoprotein Ea

apolipoprotein E
Top mentioned proteins: apolipoprotein E, AGE, HAD, CAN, V1a
Papers on apolipoprotein E
Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis.
New
Impact
Brooks et al., Maastricht, Netherlands. In Jama, 19 Jun 2015
Main Outcomes and Measures: Estimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) ε4 status, using the generalized estimating equations method.
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis.
New
Impact
Zetterberg et al., Maastricht, Netherlands. In Jama, 19 Jun 2015
Main Outcomes and Measures: Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.
Methyl-γ-butyrobetaine decreases levels of acylcarnitines and attenuates the development of atherosclerosis.
New
Dambrova et al., Rīga, Latvia. In Vascul Pharmacol, 16 Jun 2015
METHODS: Apolipoprotein E knockout (apoE-/-) mice were treated with methyl-GBB, L-carnitine or GBB for 4 months.
Proteomic analysis of Plasmodium falciparum induced alterations in humans from different endemic regions of India to decipher malaria pathogenesis and identify surrogate markers of severity.
New
Srivastava et al., Mumbai, India. In J Proteomics, 14 Jun 2015
Identified proteins including serum amyloid A, C-reactive protein, apolipoprotein E and haptoglobin, which exhibited sequential alterations in their serum abundance in different severity levels of malaria, could serve as potential predictive markers for disease severity.
Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.
New
Gomez-Guerrero et al., Madrid, Spain. In Diabetologia, 28 May 2015
METHODS: Apolipoprotein E-deficient mice with diabetes induced by streptozotocin were treated with a cell-permeable peptide derived from the IKKα/β NBD region.
The role of APOE-ɛ4 and beta amyloid in the differential rate of recovery from ECT: a review.
Review
New
Martins et al., Australia. In Transl Psychiatry, Dec 2014
A narrative review of the research literature on carriage of the apolipoprotein E ɛ4 allele (APOE-ɛ4) and the protein biomarker beta amyloid (Aβ) with ECT cognitive outcome was undertaken.
Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment.
Review
New
Leng et al., Dalian, China. In Clin Interv Aging, Dec 2014
It is worth mentioning that the therapeutic effects of these drugs are influenced by the apolipoprotein E (APOE)-ε4 genotype.
HDL biogenesis, remodeling, and catabolism.
Review
New
Chroni et al., Boston, United States. In Handb Exp Pharmacol, Dec 2014
Similarly to apoA-I, apolipoprotein E and apolipoprotein A-IV were shown to form discrete HDL particles containing these apolipoproteins which may have important but still unexplored functions.
Additional mechanisms conferring genetic susceptibility to Alzheimer's disease.
Review
New
Medina et al., Madrid, Spain. In Front Cell Neurosci, Dec 2014
Besides apolipoprotein E, that presents a strong association with the disease (OR∼4), the rest of these genes have moderate or low degrees of association, with OR ranging from 0.88 to 1.23.
Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE.
New
Alzheimer's Disease Neuroimaging Initiative et al., Melbourne, Australia. In Nat Commun, Dec 2014
We show that baseline CSF ferritin levels were negatively associated with cognitive performance over 7 years in 91 cognitively normal, 144 mild cognitive impairment (MCI) and 67 AD subjects, and predicted MCI conversion to AD. Ferritin was strongly associated with CSF apolipoprotein E levels and was elevated by the Alzheimer's risk allele, APOE-ɛ4.
Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study.
New
Meyer-Lindenberg et al., Mannheim, Germany. In Alzheimers Res Ther, Dec 2014
In the present study, we investigated potential apolipoprotein E (APOE)-dependent effects on the extent and cognitive impact of WM hyperintensities in patients with AD.
Cholesterol and metal ions in Alzheimer's disease.
Review
New
Impact
Lim et al., Ann Arbor, United States. In Chem Soc Rev, Nov 2014
For example, (a) cholesterol has been shown to be misregulated in AD-afflicted brains, and the aberrant activity of proteins (particularly, apolipoprotein E (ApoE) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGR)) has been linked to cholesterol-related AD exacerbation; (b) dyshomeostasis of metal ions associated with misfolded proteins (i.e., amyloid-β (Aβ) aggregates) found in the brains of AD patients is shown to promote oxidative stress leading to the malfunction of multiple proteins, including cytochrome c oxidase (CcO), and Cu/Zn superoxide dismutase (SOD1); (c) metal ion misregulation has also been observed to disrupt the activity of proteins (e.g., HMGR, low-density lipoproteins (LDL)), required for cholesterol production and regulation.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
New
Impact
Bapineuzumab 301 and 302 Clinical Trial Investigators et al., Jarash, Jordan. In N Engl J Med, Feb 2014
METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers.
Apolipoprotein E in Alzheimer's disease: an update.
Review
Impact
Hardy et al., Qingdao, China. In Annu Rev Neurosci, 2013
Apolipoprotein E (APOE) has been irrefutably recognized as the major genetic risk factor, with semidominant inheritance, for LOAD.
Review
Lau et al., Rockville, United States. In Unknown Journal, 0001
OBJECTIVE: We assessed four pharmacogenetic tests: 1) cytochrome P450, subfamily IIC, polypeptide 9 (CYP2C9), 2) vitamin K epoxide reductase subunit protein 1 (VKORC1), 3) apolipoprotein E (Apo E), and 4) methylenetetrahydrofolate reductase (MTHFR) for their associations with patient’s response to therapy with warfarin (CYP2C9 and VKORC1), statins (Apo E), or antifolate chemotherapy (MTHFR).
share on facebooktweetadd +1mail to friends